GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Athersys Inc (OTCPK:ATHXQ) » Definitions » Scaled Net Operating Assets

Athersys (Athersys) Scaled Net Operating Assets : -1.80 (As of Sep. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Athersys Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Athersys's operating assets for the quarter that ended in Sep. 2023 was $6.41 Mil. Athersys's operating liabilities for the quarter that ended in Sep. 2023 was $25.25 Mil. Athersys's Total Assets for the quarter that ended in Jun. 2023 was $10.48 Mil. Therefore, Athersys's scaled net operating assets (SNOA) for the quarter that ended in Sep. 2023 was -1.80.


Athersys Scaled Net Operating Assets Historical Data

The historical data trend for Athersys's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Athersys Scaled Net Operating Assets Chart

Athersys Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.24 -0.19 -0.47 -0.19 -0.40

Athersys Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.61 -0.68 -0.93 -0.70 -1.80

Competitive Comparison of Athersys's Scaled Net Operating Assets

For the Biotechnology subindustry, Athersys's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Athersys's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Athersys's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Athersys's Scaled Net Operating Assets falls into.



Athersys Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Athersys's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2022 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2022 )
=(Operating Assets (A: Dec. 2022 )-Operating Liabilities (A: Dec. 2022 ))/Total Assets (A: Dec. 2021 )
=(18.693-42.897)/60.184
=-0.40

where

Operating Assets(A: Dec. 2022 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=27.731 - 9.038
=18.693

Operating Liabilities(A: Dec. 2022 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=51.582 - 7.939 - 0.746
=42.897

Athersys's Scaled Net Operating Assets (SNOA) for the quarter that ended in Sep. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Sep. 2023 )
=(Operating Assets (Q: Sep. 2023 )-Operating Liabilities (Q: Sep. 2023 ))/Total Assets (Q: Jun. 2023 )
=(6.408-25.246)/10.477
=-1.80

where

Operating Assets(Q: Sep. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=7.428 - 1.02
=6.408

Operating Liabilities(Q: Sep. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=43.823 - 0 - 18.577
=25.246

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Athersys Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Athersys's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Athersys (Athersys) Business Description

Industry
Traded in Other Exchanges
N/A
Address
3201 Carnegie Avenue, Cleveland, OH, USA, 44115-2634
Athersys Inc is a biotechnology company engaged in the field of regenerative medicine. It consists of research, clinical development, manufacturing, and manufacturing process development activities. The firm's main product is Multistem cell therapy. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and certain pulmonary conditions. Its revenue has been derived from corporate collaborations, license agreements, and government grants.
Executives
Neema Mayhugh director 3201 CARNEGIE AVE, CLEVELAND OH 44115
Joseph Patrick Nolan director 100 PARK LANE, LAKE BLUFF IL 60044
Daniel A. Camardo director, officer: Chief Executive Officer ATHERSYS, INC., 3201 CARNEGIE AVE, CLEVELAND OH 44115
Maia Hansen officer: Chief Operating Officer 16430 N. SCOTTSDALE ROAD, SCOTTSDALE AZ 85254
Kasey Rosado officer: Interim, CFO 485 LEXINGTON AVE 10TH FLOOR, NEW YORK NY 10017
Ismail Kola director 3201 CARNEGIE AVENUE, CLEVELAND OH 44115
Ivor Macleod officer: Chief Financial Officer 3201 CARNEGIE AVENUE, CLEVELAND OH 44115-2634
William Jr Lehmann officer: President 3201 CARNEGIE AVENUE, CLEVELAND OH 44115
John J Harrington director, officer: Chief Scientific Officer 3201 CARNEGIE AVENUE, CLEVELAND OH 44115
Laura K Campbell officer: Vice President 3201 CARNEGIE AVENUE, CLEVELAND OH 44115
Katherine Bach Kalin director 3201 CARNEGIE AVENUE, CLEVELAND OH 44115
Baiju R. Shah director ONE INVACARE WAY, ELYRIA OH 44035
Jane Wasman director C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Kenneth H Traub director
Tadahisa Kagimoto director, 10 percent owner HEALIOS K.K., WORLD TRADE CENTER BLDG., 15F, 2-4-1 HAMAMATSUCHO, MINATO-KU, TOKYO M0 1056115